Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.

Autor: Joensuu H; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Fraser J; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Wildiers H; Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium., Huovinen R; Turku University Hospital, Turku, Finland., Auvinen P; Department of Oncology, Kuopio University Hospital, Kuopio, Finland., Utriainen M; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Villman KK; Örebro University Hospital, Örebro, Sweden., Halonen P; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Granstam-Björneklett H; Västerås Central Hospital, Västerås, Sweden., Tanner M; Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland., Sailas L; Vaasa Central Hospital, Vaasa, Finland.; North Karelia Central Hospital, Joensuu, Finland., Turpeenniemi-Hujanen T; Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland., Yachnin J; Center for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden., Huttunen T; EstiMates Ltd, Turku, Finland., Neven P; Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium., Canney P; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Harvey VJ; Auckland City Hospital, Auckland, New Zealand., Kellokumpu-Lehtinen PL; Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland., Lindman H; Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden.

Publikováno v: JAMA network open [JAMA Netw Open] 2024 Aug 01; Vol. 7 (8), pp. e2429772. Date of Electronic Publication: 2024 Aug 01.

A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland.

Autor: Ollila E; Cancer Society of Finland, P.O. Box 238, 00131, Helsinki, Finland. eeva.ollila@cancer.fi.; Faculty of Social Sciences, University of Tampere, Tampere, Finland. eeva.ollila@cancer.fi., Kataja V; Kaiku Health, Part of ELEKTA, Helsinki, Finland.; University of Eastern Finland, Jyväskylä, Finland., Sailas L; Cancer Center, Joint Municipal Authority for North Karelia Social and Health Care Services (SiunSote), Joensuu, Finland.

Publikováno v: Journal of pharmaceutical policy and practice [J Pharm Policy Pract] 2022 Aug 29; Vol. 15 (1), pp. 52. Date of Electronic Publication: 2022 Aug 29.

PD-028 - Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study

Autor: Osterlund, P., Lamminmäki, A., Soveri, L., Ålgars, A., Salminen, T., Kallio, R., Ristamäki, R., Halonen, P., Osterlund, E., Rajanen, A., Lantto, E., Ovissi, A., Nordin, A., Murashev, M., Aroviita, L., Jekunen, A., Lindvall-Andersson, R., Nyandoto, P., Kononen, J., Kokko, R., Sjöstrand, A., Isoniemi, H., Kotkavaara, M., Kellokumpu, I., Tuomisto-Huttunen, T., Sainast, A., Hermanson, T., Tuominiemi, J., Möykkynen, K., Isokangas, O., Klaavuniemi, T., Kaleva-Kerola, J., Männistö, E., Sailas, L., Huuhtanen, R., Mansisto, A., Poussa, T.

Publikováno v: In Annals of Oncology July 2019 30 Supplement 4:iv119-iv119

382 - Nationwide survey on patients’ and professionals’ expectations on prognosis of metastatic colorectal cancer (mCRC)

Autor: Sailas, L., Kataja, V., Kuoppala, J.

Publikováno v: In European Journal of Cancer February 2017 72 Supplement 1:S50-S50

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Autor: Joensuu H; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Fraser J; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Wildiers H; University Hospitals Leuven, Leuven, Belgium., Huovinen R; Department of Oncology, Turku University Central Hospital, Turku, Finland., Auvinen P; Department of Oncology, Kuopio University Hospital, Kuopio, Finland., Utriainen M; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Nyandoto P; Päijät-Häme Central Hospital, Lahti, Finland., Villman KK; Örebro University Hospital, Örebro, Sweden., Halonen P; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Granstam-Björneklett H; Västerås Central Hospital, Västerås, Sweden., Lundgren L; Skåne University Hospital, Lund, Sweden., Sailas L; Vaasa Central Hospital, Vaasa, Finland.; North Carelia Central Hospital, Joensuu, Finland., Turpeenniemi-Hujanen T; Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland., Tanner M; Department of Oncology, Tampere University Hospital, Tampere, Finland., Yachnin J; Eskilstuna Hospital, Eskilstuna, Sweden., Ritchie D; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Johansson O; Landspitali University Hospital, Reykjavik, Iceland., Huttunen T; 4Pharma, Turku, Finland., Neven P; University Hospitals Leuven, Leuven, Belgium., Canney P; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Harvey VJ; Auckland City Hospital, Auckland, New Zealand., Kellokumpu-Lehtinen PL; Department of Oncology, Tampere University Hospital, Tampere, Finland., Lindman H; Uppsala University Hospital, Uppsala, Sweden.

Publikováno v: JAMA oncology [JAMA Oncol] 2018 Sep 01; Vol. 4 (9), pp. 1199-1206.